Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome
{{output}}
Myelodysplastic syndrome is a heterogeneous disease with survival probabilities ranging from a few months to several years. Allogeneic hematopoietic cell transplantation (HCT) remains the only curative treatment. Although access (up to 75 years) and outcome of... ...